logo
Plus   Neg
Share
Email

Vodafone Says 20% Of Supplier Selection Based On Commitments To Diversity & Environment

Vodafone Group Plc. (VOD.L,VOD) said that, from October onwards, 20% of supplier selection criteria will be based on commitments to diversity and the environment.

The company said it will evaluate suppliers on their commitments to diversity, inclusion and the environment when they tender for new work, ensuring that Vodafone's supply chain contributes towards Vodafone's purpose to improve the lives of 1 billion people, while halving its environmental impact by 2025.

For new tenders, suppliers will be asked to demonstrate policies and procedures that support diversity in the workplace, including gender, ethnicity, LGBT+, age and disability criteria, Vodafone said in a statement. It will include policies on equal pay, and whether suppliers have publicly reported targets in relation to the percentage of female employees company-wide and at senior management levels.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walmart and Sam's Club announced options for customers to safely dispose unused, unwanted and expired medication throughout the year. With this, the retail giant aims to help the public from potential danger for misuse and abuse of prescription medications. On Saturday, October 24, the company will host in-person medication disposal events at select store and club locations across U.S. Telecom giant AT&T, Inc. reported Thursday a 24 percent decline in profit for the third quarter, primarily hurt by lower revenues across all its operating segments amid the impact from COVID-19 pandemic. Adjusted earnings for the quarter met analysts' expectations, while quarterly revenues topped their estimates. A Brazilian volunteer, who participated in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University, has died, Brazilian health authority Anvisa said. Oxford university reportedly confirmed the plan to continue the trial after careful assessment that there have been no concerns about safety of the clinical trial.
Follow RTT